NCT02398240 2023-10-26Brentuximab for Newly Diagnosed Hodgkin DiseaseNew York Medical CollegePhase 2 Completed40 enrolled
NCT00337194 2015-02-23SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin LymphomaNational Cancer Institute (NCI)Phase 2 Completed30 enrolled 13 charts
NCT00237627 2012-05-18Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast CancerUNC Lineberger Comprehensive Cancer CenterPhase 1/2 Completed107 enrolled